607 related articles for article (PubMed ID: 20446864)
1. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
Miller M
Expert Opin Pharmacother; 2010 Jun; 11(9):1569-78. PubMed ID: 20446864
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
Cornely OA
Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
[TBL] [Abstract][Full Text] [Related]
3. Fidaxomicin for the treatment of Clostridium difficile infections.
Whitman CB; Czosnowski QA
Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
[TBL] [Abstract][Full Text] [Related]
4. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
Sullivan KM; Spooner LM
Ann Pharmacother; 2010 Feb; 44(2):352-9. PubMed ID: 20071495
[TBL] [Abstract][Full Text] [Related]
5. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
Lancaster JW; Matthews SJ
Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
[TBL] [Abstract][Full Text] [Related]
6. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection.
Venugopal AA; Johnson S
Clin Infect Dis; 2012 Feb; 54(4):568-74. PubMed ID: 22156854
[TBL] [Abstract][Full Text] [Related]
7. Fidaxomicin: first-in-class macrocyclic antibiotic.
Mullane KM; Gorbach S
Expert Rev Anti Infect Ther; 2011 Jul; 9(7):767-77. PubMed ID: 21810048
[TBL] [Abstract][Full Text] [Related]
8. Clostridium difficile infection in older adults: a review and update on its management.
Kee VR
Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
[TBL] [Abstract][Full Text] [Related]
9. Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
[TBL] [Abstract][Full Text] [Related]
10. Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Hardesty JS; Juang P
Pharmacotherapy; 2011 Sep; 31(9):877-86. PubMed ID: 21923589
[TBL] [Abstract][Full Text] [Related]
11. Role of fidaxomicin for the treatment of Clostridium difficile infection.
Juang P; Hardesty JS
J Pharm Pract; 2013 Oct; 26(5):491-7. PubMed ID: 24064437
[TBL] [Abstract][Full Text] [Related]
12. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Crawford T; Huesgen E; Danziger L
Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
[TBL] [Abstract][Full Text] [Related]
13. Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxis.
Hostler CJ; Chen LF
Expert Opin Pharmacother; 2013 Aug; 14(11):1529-36. PubMed ID: 23683070
[TBL] [Abstract][Full Text] [Related]
14. Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections.
Soriano MM; Liao S; Danziger LH
Expert Rev Anti Infect Ther; 2013 Aug; 11(8):767-76. PubMed ID: 23977933
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and management of Clostridium difficile infection.
Dupont HL
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1216-23; quiz e73. PubMed ID: 23542332
[TBL] [Abstract][Full Text] [Related]
16. Best strategies in recurrent or persistent Clostridium difficile infection.
Cocanour CS
Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
[TBL] [Abstract][Full Text] [Related]
17. Fidaxomicin: a new option for the treatment of Clostridium difficile infection.
Johnson AP; Wilcox MH
J Antimicrob Chemother; 2012 Dec; 67(12):2788-92. PubMed ID: 22865382
[TBL] [Abstract][Full Text] [Related]
18. Fidaxomicin--the new drug for Clostridium difficile infection.
Vaishnavi C
Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
[TBL] [Abstract][Full Text] [Related]
19. Fidaxomicin, a new treatment for Clostridium difficile infections.
Epstein L; Golan Y
Drugs Today (Barc); 2012 Feb; 48(2):101-8. PubMed ID: 22384450
[TBL] [Abstract][Full Text] [Related]
20. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN
Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
